SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-20-016044
Filing Date
2020-11-09
Accepted
2020-11-09 09:00:29
Documents
80
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrsn-20200930.htm   iXBRL 10-Q 1218180
2 EX-31.1 exhibit31110-qfy2020q3.htm EX-31.1 10109
3 EX-31.2 exhibit31210-qfy2020q3.htm EX-31.2 10097
4 EX-32.1 exhibit32110-qfy2020q3.htm EX-32.1 5838
  Complete submission text file 0001628280-20-016044.txt   6307195

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrsn-20200930.xsd EX-101.SCH 52663
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrsn-20200930_cal.xml EX-101.CAL 79323
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrsn-20200930_def.xml EX-101.DEF 250346
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrsn-20200930_lab.xml EX-101.LAB 599264
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrsn-20200930_pre.xml EX-101.PRE 404816
10 EXTRACTED XBRL INSTANCE DOCUMENT mrsn-20200930_htm.xml XML 978525
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38129 | Film No.: 201296311
SIC: 2834 Pharmaceutical Preparations